Milestone reached in enrollment facilitates evaluation of EasyM® for clinical utility in monitoring non-invasive multiple myeloma. Located in Kitchener, Ontario, the development company Rapid Novor Inc. announced on April 7, 2026 that their blood-based minimal residual disease (MRD) test called EasyM® is making progress. This test aims to enhance monitoring for multiple myeloma without invasive procedures.